ALKEM LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of ALKEM LABORATORIES have increased by 19.96% YoY .
The Earnings Per Share (EPS) of ALKEM LABORATORIES has decreased by -40.20 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
ALKEM LABORATORIES Last 5 Annual Financial Results
[BOM: 539523|NSE : ALKEM]
| Consolidated | Mar2023 | Mar2022 | Mar2021 | Mar2020 | Mar2019 |
|---|---|---|---|---|---|
| Revenues | ₹10,634 Cr | ₹8,865 Cr | ₹8,344 Cr | ₹7,357 Cr | ₹6,392 Cr |
| Expenses | ₹8,581 Cr | ₹6,923 Cr | ₹6,871 Cr | ₹6,242 Cr | ₹5,383 Cr |
| Operating Profit (Excl OI) | ₹2,053 Cr | ₹1,942 Cr | ₹1,473 Cr | ₹1,115 Cr | ₹1,009 Cr |
| Other Income | ₹163 Cr | ₹233 Cr | ₹104 Cr | ₹88 Cr | ₹115 Cr |
| Interest | ₹52 Cr | ₹59 Cr | ₹65 Cr | ₹55 Cr | ₹55 Cr |
| Depreciation | ₹304 Cr | ₹275 Cr | ₹253 Cr | ₹193 Cr | ₹143 Cr |
| Profit Before Tax | ₹1,844 Cr | ₹1,842 Cr | ₹1,260 Cr | ₹955 Cr | ₹926 Cr |
| Profit After Tax | ₹1,680 Cr | ₹1,618 Cr | ₹1,149 Cr | ₹774 Cr | ₹638 Cr |
| Consolidated Net Profit | ₹1,646 Cr | ₹1,585 Cr | ₹1,127 Cr | ₹761 Cr | ₹631 Cr |
| Earnings Per Share (Rs) | ₹82.32 | ₹137.65 | ₹132.58 | ₹94.28 | ₹63.61 |
| PAT Margin (%) | 5.61 | 11.00 | 12.34 | 9.27 | 7.22 |
| ROE(%) | 11.39 | 20.99 | 23.91 | 19.82 | 15.02 |
| ROCE(%) | 13.09 | 18.69 | 22.56 | 18.71 | 16.49 |
| Total Debt/Equity(x) | 0.14 | 0.30 | 0.23 | 0.26 | 0.17 |
Key Financials |
||
| Market Cap | : | ₹ 58,621.9 Cr |
| Revenue (TTM) | : | ₹ 12,634.4 Cr |
| Net Profit(TTM) | : | ₹ 1,574.7 Cr |
| EPS (TTM) | : | ₹ 131.7 |
| P/E (TTM) | : | 37.2 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| ALKEM LABORATORIES | 3.3% | 2.3% | 42% |
| SUN PHARMACEUTICAL INDUSTRIES | -2.3% | -6.5% | 55.3% |
| CIPLA | 4.1% | -4.8% | 55.6% |
| DR REDDYS LABORATORIES | 4% | 0.8% | 29.4% |
| ZYDUS LIFESCIENCES | -1.2% | -5.2% | 83.9% |
| DIVIS LABORATORIES | 7.8% | 17.4% | 20.3% |
| MANKIND PHARMA | 1.3% | 7% | NA |
| TORRENT PHARMACEUTICALS | 3.9% | 5.1% | 66.1% |
| LUPIN | 0.6% | 0.5% | 127.2% |
ALKEM LABORATORIES Revenues
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 19.96 % |
| 5 Yr CAGR | 13.57 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2023 | ₹10,634 Cr | 19.96 | |
| Mar2022 | ₹8,865 Cr | 6.24 | |
| Mar2021 | ₹8,344 Cr | 13.42 | |
| Mar2020 | ₹7,357 Cr | 15.10 | |
| Mar2019 | ₹6,392 Cr | - | |
ALKEM LABORATORIES Operating Profit
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 5.69 % |
| 5 Yr CAGR | 19.43 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2023 | ₹2,053 Cr | 5.69 | |
| Mar2022 | ₹1,942 Cr | 31.83 | |
| Mar2021 | ₹1,473 Cr | 32.17 | |
| Mar2020 | ₹1,115 Cr | 10.49 | |
| Mar2019 | ₹1,009 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -11.91 % |
| 5 Yr CAGR | 5.16 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2023 | 19.3% | -11.91 | |
| Mar2022 | 21.91% | 24.07 | |
| Mar2021 | 17.66% | 16.57 | |
| Mar2020 | 15.15% | -3.99 | |
| Mar2019 | 15.78% | - | |
ALKEM LABORATORIES Profit After Tax
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | 3.82 % |
| 5 Yr CAGR | 27.08 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2023 | ₹1,646 Cr | 3.82 | |
| Mar2022 | ₹1,585 Cr | 40.63 | |
| Mar2021 | ₹1,127 Cr | 48.20 | |
| Mar2020 | ₹761 Cr | 20.54 | |
| Mar2019 | ₹631 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -49.00 % |
| 5 Yr CAGR | -6.11 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2023 | 5.61 % | -49.00 | |
| Mar2022 | 11 % | -10.86 | |
| Mar2021 | 12.34 % | 33.12 | |
| Mar2020 | 9.27 % | 28.39 | |
| Mar2019 | 7.22 % | - | |
ALKEM LABORATORIES Earnings Per Share (EPS)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | -40.20 % |
| 5 Yr CAGR | 6.66 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2023 | ₹82 | -40.20 | |
| Mar2022 | ₹138 | 3.82 | |
| Mar2021 | ₹133 | 40.62 | |
| Mar2020 | ₹94 | 48.22 | |
| Mar2019 | ₹64 | - | |
ALKEM LABORATORIES Return on Capital Employed (ROCE)
[BOM: 539523|NSE : ALKEM]
| Y-o-Y | -29.96 % |
| 5 Yr CAGR | -5.61 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2023 | 13.09% | -29.96 | |
| Mar2022 | 18.69% | -17.15 | |
| Mar2021 | 22.56% | 20.58 | |
| Mar2020 | 18.71% | 13.46 | |
| Mar2019 | 16.49% | - | |
ALKEM LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹4,901.5 |
| Current MarketCap | : | ₹ 58,621.9 Cr |
| Updated EOD on | : | Apr 26,2024 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| ALKEM LABORATORIES | 3.3% |
2.3% |
42% |
| SENSEX | 0.9% |
1.5% |
23.6% |
ALKEM LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE MIDSMALLCAP | 4% | 9.7% | 67.3% |
| S&P BSE MID CAP | 4% | 7.6% | 67.4% |
| S&P BSE 400 MIDSMALLCAP | 3.8% | 9.1% | 62% |
| S&P BSE 150 MIDCAP | 3.6% | 7.7% | 59.6% |
| S&P BSE HEALTHCARE | 3% | 4% | 55.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY200 MOMENTUM 30 INDEX | 4.8% | 7.4% | 72.2% |
| NIFTY FREE MIDCAP 100 | 4% | 7.6% | 62.8% |
| NIFTY MID SMALL400 | 3.9% | 9.6% | 64.8% |
| NIFTY MIDCAP150 | 3.7% | 8% | 60.4% |
| NIFTY MIDCAP 50 | 3.6% | 5.9% | 61.3% |
You may also like the below Video Courses
FAQ about ALKEM LABORATORIES Financials
How the annual revenues of ALKEM LABORATORIES have changed ?
The Revenues of ALKEM LABORATORIES have increased by 19.96% YoY .
How the Earnings per Share (EPS) of ALKEM LABORATORIES have changed?
The Earnings Per Share (EPS) of ALKEM LABORATORIES has decreased by -40.20 % YoY .
Check out Intrinsic Value of Peers of ALKEM LABORATORIES
Compare Stock Analytics of Peers of ALKEM LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
